NCT04487106View on ClinicalTrials.gov

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 21, 2020

Primary Completion Date

February 9, 2023

Study Completion Date

January 25, 2024

Conditions
Recurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic Syndrome
Interventions
DRUG

Azacitidine

Given IV or SC

DRUG

Trametinib

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT04487106 - Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter